Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
IT1-H82W1 | Human | Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free |
|
||
IT1-H52W1 | Human | Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free |
|
Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 1-16 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Crohn Disease; Multiple Sclerosis | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Multiple Sclerosis; Crohn Disease | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease | Details |
Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Crohn Disease; Multiple Sclerosis | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Multiple Sclerosis; Crohn Disease | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AS-101 | PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 | Phase 2 Clinical | Biomas Ltd | Alopecia; HIV Infections; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Dermatitis, Atopic; Condylomata Acuminata | Details |
ATL-1102 | ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis; Muscular Dystrophy, Duchenne | Details |
Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
LLP2A alendronate | Phase 1 Clinical | University Of California | Osteonecrosis; Osteoporosis; Bone Diseases, Metabolic; Bone Diseases | Details | |
RBx-7796 | RBx-7796 | Clinical | Sun Pharmaceutical Industries Ltd | Rhinitis, Allergic; Asthma | Details |
AS-101 | PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 | Phase 2 Clinical | Biomas Ltd | Alopecia; HIV Infections; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Dermatitis, Atopic; Condylomata Acuminata | Details |
ATL-1102 | ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis; Muscular Dystrophy, Duchenne | Details |
Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
LLP2A alendronate | Phase 1 Clinical | University Of California | Osteonecrosis; Osteoporosis; Bone Diseases, Metabolic; Bone Diseases | Details | |
RBx-7796 | RBx-7796 | Clinical | Sun Pharmaceutical Industries Ltd | Rhinitis, Allergic; Asthma | Details |
This web search service is supported by Google Inc.